Psychedelic Therapy in Vermont, Ohio & West Virginia: Current Status

Why These Three States Are Worth Covering Together

Vermont, Ohio, and West Virginia are not often grouped in the same conversation. One sits in the progressive Northeast; the other two are solidly conservative, Midwestern and Appalachian. But people in all three states are searching for the same thing: honest information about what psychedelic-assisted therapy options exist where they live.

The short answer is that all three states share the same legal baseline: ketamine is available, psilocybin is not. But the policy trajectories differ considerably, and understanding those differences helps you plan realistically. For a broader national view, see our overview post: Is Psychedelic Therapy Legal in the United States?

Vermont: The Most Active Policy Process in the Region

Vermont is worth starting with because it has moved further, faster, than most states on psychedelic policy. That said, “further faster” does not mean legal access to psilocybin yet. Here is what has actually happened.

In May 2024, Governor Phil Scott signed Act 126, which created the Psychedelic Therapy Advisory Working Group. The nine-member group, composed of mental health professionals, physicians, and policy experts, met five times between July and October 2024 to review clinical research and examine programs in Oregon and Colorado. Their final report, published November 2024, reached a nuanced conclusion: the group found general consensus around the potential for psilocybin-assisted therapy for depression, anxiety, and end-of-life care, but did not recommend launching a statewide program at this time. The disagreements centered on how far Vermont should move ahead of federal approval, and whether Oregon’s model (which operates outside the traditional healthcare system) was appropriate to replicate.

Importantly, the report did not close the door. The conversation continued into the 2025-2026 legislative session. Vermont House Bill 452 (2025) proposed decriminalizing psilocybin mushrooms and establishing a therapeutic consultation program, though it faced opposition from the state’s Substance Misuse Prevention Council. A separate 2026 bill (H.859) proposed establishing a formal Psychedelic Therapy Advisory Board with powers to review clinical evidence, propose a pilot program, and fund harm reduction training for healthcare professionals, with a proposed effective date of July 1, 2026.

So psilocybin Vermont legal status as of May 2026 is this: no licensed program, no decriminalization passed, but active legislation in progress and a state policy infrastructure that is genuinely engaging the question. Vermont is not waiting for things to happen nationally. It is building its own process, and that process is ongoing.

What is available right now in Vermont: ketamine-assisted therapy. The advisory working group’s own report noted that ketamine therapy is already used across multiple Vermont locations to treat mental health conditions, with providers including IV administration clinics and therapy-integrated models. Ketamine is a Schedule III substance and legal nationwide with a prescription, including in Vermont.

Ohio: Legal Ketamine, Research Activity, and Pending Legislation

For anyone exploring psychedelic therapy Ohio, the practical starting point is ketamine. It is the only legally available psychedelic-assisted therapy in the state as of 2026. Psilocybin and MDMA remain Schedule I under both Ohio Revised Code Section 3719 and federal law, with no statewide decriminalization. Columbus, Cleveland, and Cincinnati have not passed local deprioritization resolutions.

That does not mean Ohio is inactive on the research side. The Ohio State University’s Center for Psychedelic Drug Research and Education (CPDRE) is engaged in active clinical trials, including a Phase III study of a psilocybin compound for treatment-resistant depression developed by COMPASS Pathways. Participation in these trials is a legal pathway for some patients, though enrollment is limited and conditions for eligibility are strict.

On the legislative side, Ohio HB 249 (2025) proposed a psilocybin-assisted therapy pilot program. As of the time of writing, it has not advanced. An earlier bill (HB 58, 2023) addressed psilocybin and MDMA for PTSD and depression research but also did not pass. Ohio’s cannabis legalization via Issue 2 in November 2023 does not cover psilocybin.

What this means practically: if you are in Ohio and looking for a professionally supported altered-state experience for depression, PTSD, or anxiety, ketamine-assisted psychotherapy is the accessible, legal option. A growing number of Ohio providers offer ketamine-assisted psychotherapy (KAP) that includes preparation sessions, monitored dosing, and integration support. The quality of that support varies significantly by provider, which is where guidance becomes important.

West Virginia: Federal Baseline, Early Signals

West Virginia is the most conservative-leaning of the three states on this issue. As of May 2026, the state has no psychedelic reform legislation that has passed into law, and psilocybin remains fully illegal under both state and federal law. No city-level decriminalization efforts have advanced.

There are early signals worth noting. West Virginia HB 3343 (2025) was introduced to address rescheduling of pharmaceutical psilocybin if and when the FDA approves such a formulation, placing it on the more cautious end of the national policy spectrum. This type of bill, sometimes called a “rescheduling trigger” law, does not legalize anything on its own; it simply prepares state law to align with a potential federal change. The bill did not advance through the 2025 session.

Ketamine therapy West Virginia follows the same national rule: it is legal with a prescription, as ketamine is a Schedule III substance. IV ketamine clinics and esketamine (Spravato) programs operate in the state, and telehealth-based ketamine prescribing expanded significantly following DEA temporary rule extensions through December 2026. For West Virginians dealing with treatment-resistant depression, PTSD, or anxiety, ketamine therapy is the most accessible, legally clear option right now.

West Virginia has high rates of mental health need and limited access to conventional psychiatric care in many rural areas. That gap is part of why ketamine’s accessibility matters more here than in states with denser healthcare infrastructure.

A Note on the April 2026 Federal Executive Order

In April 2026, President Trump signed an executive order directing federal agencies to accelerate research and FDA review for psychedelic compounds including psilocybin, ibogaine, ketamine, LSD, and MDMA, and allocated $50 million to support state programs developing psychedelic therapies. This is a meaningful policy signal, but it is not a change in legal access. Psilocybin remains Schedule I. Approval timelines for psilocybin-specific drugs still depend on ongoing Phase III clinical trial data. The order may speed things up, but it does not create access today in Ohio, West Virginia, or Vermont.

What These States Have in Common, and Where They Diverge

All three states share the same current legal floor: ketamine is available, psilocybin is not. The divergence is in trajectory. Vermont is the furthest along in building a formal policy process, with an active legislative session and an established advisory infrastructure. Ohio has research institutions doing meaningful clinical work and has seen multiple legislative attempts, though none have succeeded. West Virginia has the least legislative activity but is not absent from the national conversation.

For people in any of these states who are not candidates for a clinical trial and are not in a position to travel to Oregon or Colorado, ketamine-assisted therapy with genuine preparation and integration support is the most meaningful option available. Not every ketamine clinic provides that level of care. That gap in the market is significant.

What to Do Right Now

If you are in Vermont, Ohio, or West Virginia and exploring psychedelic-assisted therapy, the first practical step is understanding what you actually need and what is realistically available to you. That conversation starts with an honest assessment of your mental health history, your goals, and whether ketamine-assisted therapy with proper support might be a fit right now.

JourneyŌM’s concierge model exists precisely for this moment. We are not a clinic and we do not sell sessions. We help you understand your options, connect with vetted professional guides, and support you through preparation and integration, regardless of where you are located or where in the legal landscape things currently stand. For someone in West Virginia with limited local options, or an Ohio resident who has tried ketamine IV infusions without integration support, or a Vermonter waiting on legislation that has not passed yet, this kind of guidance is not a luxury. It is the difference between a meaningful experience and a disorienting one.

Start with our free readiness assessment or book a 15-minute call. Both are available below.